Aberdeen Group plc Has $23.25 Million Stake in Xenon Pharmaceuticals Inc. $XENE

Aberdeen Group plc lifted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 11.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 579,145 shares of the biopharmaceutical company’s stock after buying an additional 57,653 shares during the period. Aberdeen Group plc’s holdings in Xenon Pharmaceuticals were worth $23,253,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Marshall Wace LLP lifted its position in Xenon Pharmaceuticals by 34.6% during the 2nd quarter. Marshall Wace LLP now owns 1,020,254 shares of the biopharmaceutical company’s stock worth $31,934,000 after buying an additional 262,109 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at about $21,280,000. New York State Common Retirement Fund raised its holdings in Xenon Pharmaceuticals by 16.9% during the second quarter. New York State Common Retirement Fund now owns 166,472 shares of the biopharmaceutical company’s stock worth $5,211,000 after acquiring an additional 24,100 shares in the last quarter. Saturn V Capital Management LP raised its holdings in Xenon Pharmaceuticals by 13.2% during the second quarter. Saturn V Capital Management LP now owns 468,364 shares of the biopharmaceutical company’s stock worth $14,660,000 after acquiring an additional 54,653 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Xenon Pharmaceuticals by 73.6% during the second quarter. Bank of New York Mellon Corp now owns 436,020 shares of the biopharmaceutical company’s stock valued at $13,647,000 after purchasing an additional 184,873 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the transaction, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This represents a 86.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 65,302 shares of company stock worth $2,924,128. Company insiders own 4.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on XENE shares. Royal Bank Of Canada boosted their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Needham & Company LLC restated a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. JPMorgan Chase & Co. upped their price target on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $54.73.

Xenon Pharmaceuticals Stock Up 0.4%

Xenon Pharmaceuticals stock opened at $41.66 on Wednesday. The company’s 50-day moving average price is $42.49 and its two-hundred day moving average price is $40.56. The stock has a market cap of $3.22 billion, a P/E ratio of -10.71 and a beta of 0.96. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $46.60.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.